Hypertension Treatment
Jun 01, 2026
AstraZeneca’s BAXFENDY Enters the Hypertension Market: Can Aldosterone Synthase Inhibition Outperform Existing Therapies?
Summary In May 2026, the FDA approved AstraZeneca's BAXFENDY (baxdrostat), the world's first aldosterone synthase inhibitor (ASI), marking the arrival of an entirely new pharmacological class for a condition that affects 1.4 billion people globally. The approval addresses a stubborn clinical gap. Despite exi...
Read More...
Apr 08, 2024
Idorsia’s Tryvio Success in Hypertension Treatment After J&J ‘Blunder’?
After Johnson & Johnson reversed its decision last year regarding the acquisition of Tryvio (aprocitentan) in 2017, the original manufacturer of the hypertension treatment drug, Idorsia Pharmaceuticals has successfully guided the drug through the FDA approval process. The company stated that Tryvio, its endo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
